Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial by Bresalier Robert S, Sandler Robert S, Quan Hui, Bolognese James A, Oxenius Bettina, Horgan Kevin, Lines Christopher, Riddell Robert, Morton Dion, Lanas Angel, Konstam Marvin A, Baron John A, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators in The New England journal of medicine (2005).

[PMID: 15713943] PubMed


Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.